全液体DTaP-IPV-Hib-HepB疫苗对b型流感嗜血杆菌的 protective 免疫应答
该研究汇总5项III期临床试验数据,比较全液体六联疫苗DTaP-IPV-Hib-HepB与对照疫苗的抗PRP抗体应答。婴儿基础免疫后,该疫苗组达到保护性抗体阈值(≥0.15 μg/mL和≥1.0 μg/mL)的比例高于对照组;在2+1程序中,第2剂后96.6%达到≥0.15 μg/mL,72.9%达到≥1.0 μg/mL,优于对照(p<0.001)。
要点
- 婴儿基础免疫后,DTaP-IPV-Hib-HepB组的抗PRP保护性抗体比例高于对照疫苗组。
- 2+1程序中第2剂后96.6%受种者抗PRP≥0.15 μg/mL,72.9%≥1.0 μg/mL。
- 幼儿剂前,该疫苗组91.4%维持抗PRP≥0.15 μg/mL,对照组为63.4%。
核心结论
- DTaP-IPV-Hib-HepB可诱导稳健且持续的早期Hib免疫应答,在婴儿免疫后至幼儿剂前的高风险期,超过90%的受种者维持优于对照的保护性抗PRP水平。
研究设计与样本
- 汇总5项III期临床试验数据,比较DTaP-IPV-Hib-HepB与对照疫苗的抗PRP应答。
- DTaP-IPV-Hib-HepB已在6项III期临床研究中评估安全性和免疫原性,共纳入超过5200名儿童。
- 研究包含美国(2、4、6月龄)和欧洲(2、3、4、12月龄及2、4、11-12月龄)的接种程序。
主要发现
- 婴儿基础免疫后,DTaP-IPV-Hib-HepB组达到抗PRP≥0.15 μg/mL和≥1.0 μg/mL的比例均高于对照疫苗组。
- 2+1程序中第2剂后,96.6%(95%CI:94.8,97.9%)达到抗PRP≥0.15 μg/mL,72.9%(95%CI:69.2,76.4%)达到≥1.0 μg/mL,优于对照(p<0.001)。
- 同程序中幼儿剂前,DTaP-IPV-Hib-HepB组91.4%达到≥0.15 μg/mL、46.8%达到≥1.0 μg/mL;对照组分别为63.4%和17.1%。
- 幼儿剂后1个月,DTaP-IPV-Hib-HepB组99.8%达到≥0.15 μg/mL、96.6%达到≥1.0 μg/mL;对照组分别为99.5%和94.9%。
关键数值与推荐
- 保护性抗体阈值:抗PRP滴度≥0.15 μg/mL和≥1.0 μg/mL。
- 2+1程序第2剂后,DTaP-IPV-Hib-HepB组达到≥0.15 μg/mL的比例为96.6%(95%CI:94.8,97.9%),达到≥1.0 μg/mL的比例为72.9%(95%CI:69.2,76.4%),优于对照(p<0.001)。
- 幼儿剂前,DTaP-IPV-Hib-HepB组抗PRP≥0.15 μg/mL比例为91.4%,≥1.0 μg/mL比例为46.8%;对照组分别为63.4%和17.1%。
- 幼儿剂后1个月,DTaP-IPV-Hib-HepB组抗PRP≥0.15 μg/mL比例为99.8%,≥1.0 μg/mL比例为96.6%;对照组分别为99.5%和94.9%。
临床怎么用
- DTaP-IPV-Hib-HepB在婴儿基础免疫后可提供较高的Hib保护性抗体应答,支持按程序接种。
- 在幼儿剂接种前的高风险期,该疫苗可维持较高比例的保护性抗PRP水平,有助于降低Hib疾病风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: DTaP-IPV-Hib-HepB is a fully-liquid, hexavalent combination vaccine (Vaxelis™) approved for vaccination against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenzae type b (Hib). Hib capsular polysaccharide, polyribosylribitol phosphate (PRP), is conjugated to Neisseria meningitidis outer membrane protein complex (OMPC). Safety and immunogenicity of DTaP-IPV-Hib-HepB were evaluated in 6 Phase III clinical studies including > 5,200 children. Studies included vaccination schedules in the United States (2, 4, 6 months of age) and Europe (2, 3, 4, 12 months of age and 2,4,11-12 months of age). METHODS: Data pertaining to anti-PRP responses of DTaP-IPV-Hib-Hep B compared to control vaccines from 5 Phase III studies are summarized. RESULTS: Post-infant series, the percentage of participants that achieved protective antibody thresholds for PRP (anti-PRP titer ≥ 0.15 μg/mL and ≥ 1.0 μg/mL, respectively) were higher in DTaP-IPV-Hib-HepB recipients compared to recipients who received control vaccines. A high level of protective responses (96.6% at ≥ 0.15 μg/mL [95% CI:94.8, 97.9%]; 72.9% at ≥ 1.0 μg/mL [95% CI:69.2,76.4%]) were seen post-dose 2 of the 2 + 1 vaccination schedule and met superiority criteria over comparator, p-value < 0.001. In the same schedule, prior to administration of the toddler dose (in the second year of life), anti-PRP titers were higher in DTaP-IPV-Hib-HepB recipients (91.4% at ≥ 0.15 μg/mL; 46.8% at ≥ 1.0 μg/mL) as compared to recipients who received control vaccines (63.4% at ≥ 0.15 μg/mL; 17.1% at ≥ 1.0 μg/mL). One-month post-toddler dose, high levels of anti-PRP titers were achieved in both DTaP-IPV-Hib-HepB recipients (99.8% at ≥ 0.15 μg/mL; 96.6% at ≥ 1.0 μg/mL) and recipients who received control vaccines (99.5% at ≥ 0.15 μg/mL; 94.9% at ≥ 1.0 μg/mL). CONCLUSIONS: These results support that DTaP-IPV-Hib-HepB induces a robust and sustained early Hib response. During the high-risk period for Hib disease after the infant vaccine and prior to the toddler dose; >90% of recipients maintained superior protective anti-PRP levels compared to control.
引用
- Wilck MB, Jin Xu Z, Stek JE, et al. Protective immune responses against Haemophilus influenza type b elicited by a fully-liquid DTaP-IPV-Hib-HepB vaccine (VAXELIS™). Vaccine. 2021. PMID: 33541794. doi:10.1016/j.vaccine.2021.01.046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。